2023
Diabetes Technology Meeting 2022
Huang J, Yeung A, DuBord A, Wolpert H, Jacobs P, Lee W, Drincic A, Spanakis E, Sherr J, Prahalad P, Fleming A, Hsiao V, Kompala T, Lal R, Fayfman M, Ginsberg B, Galindo R, Stuhr A, Chase J, Najafi B, Masharani U, Seley J, Klonoff D. Diabetes Technology Meeting 2022. Journal Of Diabetes Science And Technology 2023, 17: 1085-1120. PMID: 36704821, PMCID: PMC10347991, DOI: 10.1177/19322968221148743.Peer-Reviewed Case Reports and Technical NotesConceptsDiabetes technologyPainful diabetic neuropathyDiabetic foot ulcersSpinal cord stimulationContinuous glucose monitoringElectronic health recordsDiabetic neuropathyFoot ulcersCord stimulationDiabetes careInsulin delivery systemsInsulin pensMeasurement of glucoseGlucose monitor dataGlucose monitoringInsulin deliveryHealth recordsContinuous glucose monitor dataNovel insulinInsulinDelivery systemDigital healthNeuropathyHypoglycemiaUlcers
2022
Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes
Berget C, Sherr JL, DeSalvo DJ, Kingman RS, Stone SL, Brown SA, Nguyen A, Barrett L, Ly TT, Forlenza GP. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. Clinical Diabetes 2022, 40: 168-184. PMID: 35669307, PMCID: PMC9160549, DOI: 10.2337/cd21-0083.Peer-Reviewed Original ResearchInsulin delivery systemsDiabetes specialty clinicPrimary care providersPrimary care settingContinuous glucose monitoring systemTherapeutic burdenDelivery systemGlucose monitoring systemDiabetes careSpecialty clinicCare settingsCare providersDiabetesInsulin pumpInsulin deliveryClinical implementationGlycemic dataGlycemiaClinicTherapyAid technologyCliniciansCare
2021
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-70-or.Peer-Reviewed Original ResearchDiabetes careDiabetic ketoacidosisStandard therapySevere hypoglycemiaSpeakers bureauEli LillyYoung childrenPrimary safety outcomePrimary effectiveness outcomeSerious adverse eventsAdvisory PanelLexicon PharmaceuticalsDaily dose requirementsType 1 diabetesNovo NordiskBoehringer Ingelheim PharmaceuticalsMannKind CorporationPermissive hyperglycemiaBaseline characteristicsHybrid closed-loop systemT1D durationAdverse eventsGlucose targetsEfficacy analysisInsulin delivery systems
2020
1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia
SHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.Peer-Reviewed Original ResearchDiabetes careGlucose targetsEli LillySerious adverse eventsHigh-fat mealRisk of hypoglycemiaAdvisory PanelType 1 diabetesChildren Aged 2MannKind CorporationHybrid closed-loop systemT1D durationAdverse eventsT1D ExchangeFat mealGlucose managementMean glucosePivotal studiesAged 2Bolus challengeDaily exerciseInvestigational deviceDlPercent timeTarget glucose1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three Continents
SHERR J, SCHWANDT A, PHELAN H, CLEMENTS M, HOLL R, BENITEZ-AGUIRRE P, MILLER K, WOELFLE J, DOVER T, MAAHS D, FRÖHLICH-REITERER E, CRAIG M. 1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three Continents. Diabetes 2020, 69 DOI: 10.2337/db20-1580-p.Peer-Reviewed Original ResearchT1D ExchangeInternational registryStable HbA1cGerman Diabetes AssociationProspective Follow-upOnset of T1D.Type 1 diabetesStudy of DiabetesAdvisory PanelEli LillyHbA1c trajectoriesT1D onsetDiabetes AssociationYears postdiagnosisAustralasian Diabetes Data NetworkDiabetes careFollow-upHarry B. Helmsley Charitable TrustGerman centersRegistryHbA1cOlder ageGreater riskDiabetes researchLexicon Pharmaceuticals978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After All
DUBOSE S, LI Z, SHAH V, SHERR J, TAMBORLANE W, BERGENSTAL R, BECK R. 926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After All. Diabetes 2019, 68 DOI: 10.2337/db19-926-p.Peer-Reviewed Original ResearchHealthy individualsMedtronic MiniMedFrequency of hypoglycemiaDuration of hypoglycemiaEli LillyPercentage of participantsHelmsley Charitable TrustNon-Hispanic whitesBoehringer Ingelheim PharmaceuticalsRace/ethnicityTakeda Pharmaceutical Company LimitedNondiabetic childrenSanofi USAdvisory PanelMean HbA1cHypoglycemic eventsKidney diseaseMulticenter studyDiabetes careMore hypoglycemiaHarry B. Helmsley Charitable TrustPercentage of timeAverage glucoseDiabetesHypoglycemia215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes
BUCKINGHAM B, FORLENZA G, SHERR J, GALDERISI A, EKHLASPOUR L, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-215-or.Peer-Reviewed Original ResearchDiabetes careMedtronic MiniMedSevere hypoglycemic eventsChildren Aged 2Advisory PanelYoung childrenMin/dAge 4.2Oral carbohydrateHybrid closed-loop systemHypoglycemic eventsGlycemic outcomesMean glucoseAged 2CGM useTherapy phaseInvestigational deviceType 1T1D therapyPercent timeMiniMedLexicon PharmaceuticalsCareUsual routineAdult participants
2018
Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions
FORLENZA G, BUCKINGHAM B, SHERR J, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1376-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsAge 14.3Percentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdolescentsConcomitant reductionSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions
SHERR J, FORLENZA G, BUCKINGHAM B, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1377-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesChildren Aged 6Min/dAdvisory PanelAge 9.9Hybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useAged 6Investigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodIncreased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.Peer-Reviewed Original ResearchRisk of microalbuminuriaSD HbA1cDiabetes careT1D Exchange Clinic RegistryShorter diabetes durationSpeakers bureauType 1 diabetesAge of diagnosisEli LillyBoehringer Ingelheim PharmaceuticalsAdvisory PanelMannKind CorporationMicroalbuminuria developmentSanofi USDiabetes durationMean HbA1cT1D durationRenal diseaseClinic registryRegistry enrollmentClinic visit recordsT1D populationMedian numberMicroalbuminuriaDiabetes InstituteSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions
BUCKINGHAM B, SHERR J, FORLENZA G, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-207-or.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdultsConcomitant reductionDays
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatment